Stites and Harbison's Biotechnology/Life Sciences Law Group includes highly experienced and dedicated attorneys focused on intellectual property protection of all aspects of biotechnology and life sciences. These include genetic engineering, immunology, monoclonal antibodies, medical devices, diagnostics, therapeutics, genetic markers, and pharmaceuticals.
The Intellectual Property (IP) members of the Biotechnology/Life Sciences Law Group have extensive backgrounds in biotechnology and related fields, including work in research laboratories, experience with Patent Examination for the USPTO, and advanced degrees, and/or technical experience in fields such as microbiology and immunology, biology, and pharmacology and cell biophysics.
The Biotechnology/Life Sciences Law Group represents a full range of clients in the biotechnological arts, ranging from major companies and universities through a number of smaller start-up businesses.
In addition to patent prosecution, the Biotechnology/Life Sciences group counsels clients on all matters relating to domestic and international intellectual property issues. This includes issues relating to infringement, validity, and freedom to operate. Our group also has deep experience in litigation, and has handled cases involving biotechnological inventions in both federal and state courts.
Stites & Harbison distinguishes itself by having ongoing relationships with intellectual property firms throughout the world. This gives our clients access to highly skilled international intellectual property counsel wherever and whenever needed.
In addition to offices in the major Southeastern cities of Atlanta, Lexington, Louisville, and Nashville, our strategically located office in Alexandria, Virginia, allows Stites & Harbison attorneys to have in-person visits with Patent Examiners at the United States Patent & Trademark Office to discuss cases and advance our clients' positions.
Examples of recent biotechnology/life sciences patents issued with Stites & Harbison patent attorneys as counsel include the following:
- 11,326,138 - Cell culture device and methods of use thereof
- 11,325,901 - Prostaglandin E synthase inhibitors and methods for utilizing the same
- 11,324,743 - Treatment for the non alcoholic steatohepatitis and fibrosis
- 11,319,304 - Pyridine quinoline compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
- 11,318,137 - Quinazoline compounds as modulators of Ras signaling
- 11,311,600 - Methods for treating obesity
- 11,311,563 - Method and composition for preventing and treating viral infections
- 11,306,069 - Benzimidazole derivatives as dual histamine H1 and histamine H4 receptor ligands
- 11,305,039 - Polymeric vascular grafts which induce neovascularization with mild to minimal inflammation and promotion of fibrovascular tissue
- 11,286,464 - Viral vaccines and methods of forming the same
- 11,285,133 - 2- or 3-imidazolines as carbapenemases inhibitors
- 11,273,210 - Arginine deiminase encapsulated inside erythrocytes and their use in treating cancer and arginase-1 deficiency
- 11,266,614 - Oral formulations of belinostat
- 11,261,166 - Lipophilic macrocyclic ligands, complexes thereof, and uses of same
- 11,248,038 - Molecular-size of elastin-like polypeptide delivery system for therapeutics modulates intrarenal deposition and bioavailability
- 11,242,342 - Isoquinoline amine compounds as mGlu
- 11,236,303 - CD34.sup.+CD41.sup.DIM megakaryocytes progenitors and uses thereof for producing proplatelet-bearing MKs and/or platelets
- 11,230,714 - Gene silencing kills emerald ash borer, an exotic, invasive tree-killing insect
- 11,225,481 - Xanthine derivative inhibitors of BET proteins
- 11,224,609 - Mithramycin derivatives having increased selectivity and anti-cancer activity
- 11,220,528 - Compositions and methods for treating pulmonary hypertension
- 11,219,623 - Inflammasome inhibition for the treatment of Parkinson's disease, Alzheimer's disease and multiple sclerosis
Biotechnology/Life Sciences is part of Stites & Harbison's larger, Intellectual Property and Technology (IPT) group, which includes more than 20 attorneys – many of whom are Registered U.S. Patent Attorneys – with experience spanning all technical disciplines. Our IPT group uses a team approach to provide clients with comprehensive intellectual property services. Our attorneys practice throughout the nation and the world in the areas of patents, trademarks, copyrights, trade secrets, licensing, computer software, e-commerce and intellectual property litigation.
NASHVILLE, Tenn.—Delta State University’s Alumni Association recently inducted Stites & Harbison, PLLC attorney Richard S. Myers, Jr., into the university’s Alumni Hall of Fame.
Stephen Weyer takes a look at what the word "hybrid" means in today's world in this Stites & Harbison Client Alert.
Mandy Decker takes a look at the different types of intellectual property in this Stites & Harbison Client Alert.
LOUISVILLE, Ky.—Stites & Harbison, PLLC attorney Mandy Wilson Decker was elected as 2023-24 Chair-Elect of the newly-formed Kentucky Bar Association (KBA) Intellectual Property (IP) Law Section.
LOUISVILLE, Ky.—Kentucky Intellectual Property Alliance (KYIPA) elects Stites & Harbison, PLLC attorney Mandy Wilson Decker as inaugural Chair of its Board of Advisors. She has served on the group’s Executive Advisory Committee since 2021.
LOUISVILLE, Ky.—Managing Intellectual Property (Managing IP) magazine recently selected Stites & Harbison, PLLC attorney Mandy Wilson Decker to the 2023 edition of Managing IP’s “Top 250 Women in IP.” This is the ninth time Decker has been honored on this list, and she is the only attorney honored from Kentucky.
LOUISVILLE, Ky. —Managing Intellectual Property (Managing IP) magazine has named nine Stites & Harbison, PLLC attorneys to the 2023 “IP Stars” list. Managing IP recognizes the most highly regarded intellectual property attorneys in the U.S.
Patent attorney Nick Stewart takes a look at the enablement challenge for genus claims under U.S. Patent Law in this Stites & Harbison Client Alert.
Recently the U.S. Patent and Trademark Office (USPTO) issued a Notice pertaining to a recent development in fraudulent communications pertaining to U.S. Trademark registrations and registration applications. Scammers are and have been accessing publicly available Trademark information and directly contacting applicants/registrants.